Bo vine colostrum as a bi o logic in clin i cal med i cine: A re view -Part II Ab stract. The value of bo vine colostrum as a bi o logic in med i cine is doc u mented in clin i cal tri als and sup ported by rel a tively large databases con tain ing case re ports and an ec dotal find ings. The main ac tions in clude an an ti bac te rial ef fect and mod u la tion of the im mune re sponse. The abil ity of bo vine colos trum con cen trates (BCC are polyvalent bo vine colostrum con cen trates pro duced from the colos trums of sev eral 100 cows) to neu tral ize lipopolysaccharides, i.e. endo tox ins aris ing from Gram-neg a tive bac te rial pathogens and to in hibit enterogenic endotoxemia in an i mal mod els as shown in the last re view to have its coun ter part in pa tient ther apy. Clin ical tri als with BCC pro vide ev i dence that oral ap pli ca tion re duces the in flux of LPS from the gut and this ap pears to be a ma jor mech anism un der ly ing its ther a peu tic ef fect in patients at risk for Gram-neg a tive sep tic shock; data from two well-con trolled clin i cal stud ies with a to tal of 100 sur gi cal pa tients have shown that the in hi bi tion of in tes ti nal LPS absorp tion mea sured af ter the ap pli ca tion of BCC not only re duced the LPS lev els in the pe riph eral blood but also in flam ma tory param e ters like IL-6 and CRP were found to be di min ished. The usual daily dose of the com mer cially avail able BCC prep a ra tion, Lactobin ® (LC1) is 10 -20 g daily, but higher doses can be used in the ma jor ity of pa tients be cause of the low in ci dence of in tol er ance prob lems. In chronic di ar rhea in volv ing severe forms of sec ond ary immunodeficiencies, pa tients re ceiv ing LC1 were disease-free for about 4 weeks but the re sponse may be lower in pa tients with AIDS. BCC is ef fec tive in in fants with hem or rhagic di ar rhea caused by in fec tions with enterohemorrhagic E. coli and re duces the like li hood of the disease pro gress ing to a hemolytic uremic syndrome. The safety of newer BCC prod ucts ob tained from BSE-free re gions seems now be yond con ten tion. In the case of LC1, which was used as a com mer cial di etary food stuff in Ger many un til 1992 and tested in three Phase 1 and 5 clin i cal stud ies (two tri als in pa tients with sec ond ary immunodeficiencies, one in sur gi cal pa tients with gas tro in tes ti nal dis orders, one in pa tients un der go ing open heart sur gery and one in pe di at ric pa tients with EHEC in fec tions), there were no cases of BSE-as so ci ated dis ease such as the new variant of Creutz feldt-Jakob dis ease. Side ef fects of clin i cal rel e vance are lim ited to pos si ble in tol er ance to lac tose and sen si tiv ity to milk pro teins as these are also pres ent in many com monly used food stuffs. Im por tant syn ergis tic ac tions with con ven tional drug ther apies have been ob served with BCC in clud ing a re duc tion in LPS plasma lev els in pa tients with Gram-neg a tive bac te rial in fec tions treated with bac te ri cidal an ti bi ot ics. In healthy per sons there are only small con centra tions of LPS de tect able in pe riph eral blood (nor mal val ues: 3 -10 pg/ ml plasma, i.e. approx i mately 0.1 EU/ml). In con trast, el e vated sys temic lev els with con cen tra tions > 300 pg/ml are com mon in pa tients with se vere Gram-neg a tive sep sis and sep tic shock. Raised LPS lev els oc cur mainly in pa tients with Gram-neg a tive bac te rial in fec tions who have been treated with bacterio cidal an ti bi otics. The LPS-low er ing ef fects of BCC are prob a bly due to the nu mer ous ac tive com ponents pres ent in BCC which have their or i gin in the in nate humoral and adap tive im mune sys tem of their bi o logic source, the cow.
Introduction
Bo vine colostrum has health-giv ing proper ties but wide spread use in ther a peu tics in the past was lim ited be cause of tech ni cal factors af fect ing the man u fac ture such as the sen si tiv ity of the lipid com po nents in raw colostrum to ox i da tion and the need for cooling fa cil i ties during storage.
The stand ardi za tion of the man u fac ture of BCC in clud ing col lec tion pro ce dures, pooling meth ods, pro duc tion of ho mog e nous batches and an a lyt i cal char ac ter iza tion have been de scribed in Part I of this re view [Struff and Sprotte 2007] . Prod uct ho mo ge ne ity in par tic u lar is a strict pre req ui site for clin i cal re search in clud ing the use of BCC as a di etary sup ple ment in the case of some groups of criti cally ill pa tients. Re ports on hyperimmune BCC are not dealt with in de tail here since they in volve a dif fer ent type of BCC (uti li zation of a lim ited num ber of colostra ob tained from cows vac ci nated with var i ous an ti gens, e.g. Shigella flexneri, E.coli strains, var i ous Protozoa, virus strains: see review by Ward et al. [2005] .
Clin i cal re search has in volved both prospec tive and con trolled clin i cal tri als and three re views have been pub lished sum ma rizing the most im por tant of the ear lier clin i cal tri als with BCC [Davidson 1996 , Kelly 2003 , Korhonen et al. 1999 . These stud ies in cluded the ther apy of di ar rhea not re spond ing to com monly used med i ca tion, e.g. in pa tients with AIDS, those with se vere pri mary and sec ond ary immunodeficiencies and in the treat ment of rotavirus in fec tions in in fants. A list of the most im por tant clin i cal stud ies carried out us ing hyperimmune prep a ra tions and polyvalent BCC are shown in Table 1 .
Part II of this re view deals mainly with clin i cal stud ies car ried out with polyvalent BCC, the pharmacodynamic po ten tial of which has been tested in an i mal stud ies and ap pro pri ate in vi tro ex per i ments for re view see [Struff and Sprotte 2007] . A se lec tion of con trolled clin i cal tri als with polyvalent BCC are listed be low and their de signs and re sults dis cussed in the following paragraphs.
Clinical indications for BCC (current options using polyvalent preparations and conforming to evidence-based medicine standards)
Some of the clin i cal stud ies with the commer cially avail able BC-con cen trate, LC1 (Lactobin ® , Biotest Pharma GmbH, Dreieich, Ger many), have been dou ble-blind and placebo-con trolled and based on com pre hen sive pharmacodynamic in ves ti ga tions. Con sid erable in for ma tion is avail able on the pro duction and anal y sis of this prod uct and it can be re garded as a pro to type bi o logic for polyvalent BCC [Lissner et al. 1996 , Stephan et al. 1990 ].
LC1 was de vel oped for clin i cal use and was man u fac tured ac cord ing to the GMPguidelines and the stud ies have been car ried out ac cord ing to GCP. How ever, as pre cau - A com mon find ing in Phase II -III clin ical stud ies and the Phase I stud ies in healthy vol un teers with LC1 was the ex cel lent tol erance and in view of the method of man u facture, this char ac ter is tic can pre sum ably be extrap o lated to LC2N with out res er va tion [Struff and Sprotte 2007] . Ad verse re ac tions are ab sent on re peated ap pli ca tion of high doses and the only con tra in di ca tions to the clin i cal ap pli ca tion of BCC known so far are an in tol er ance to lac tose and hy per sen si tiv ity to bo vine milk pro teins which disappear on withdrawal of BCC-treatment.
Use of BCC to treat chronic recurrent diarrhea in patients with AIDS and other forms of secondary immunodeficiencies
Prior to the in tro duc tion of the polypragmatic highly ac tive antiretroviral ther apy (HAART), di ar rhea and weight loss oc curred in more than 50% of pa tients with AIDS. In many pa tients, the course of this com pli ca tion was se ri ous and the prog no sis poor. In about 30% of pa tients, ev i dence for en teric pathoBo vine colostrum as a bi o logic in clin i cal med i cine: A re view -Part II 213 Ta ble 1. Clin i cal stud ies car ried out us ing bo vine colostrum con cen trates (BCC) since 1970 (eth i cal in di ca tions only).
In di ca tions in ves ti gated:
Num ber of patients en rolled In ves ti ga tors 1. Di ar rhea:
1.1. Di ar rhea due to bac te rial patho gens EHEC in fec tions (in chil dren) 30 [Huppertz et al. 1999] Helicobacter pylori (infections in in fants) 24 [Casswall et al. 1998 ] Shigellosis (in in fants) 70 [Ashraf et al. 2001] Diarrhea due to in fec tions with enterotoxic E. coli (ETEC) (in chil dren) 60 [Mietens et al. 1979] 1.2. Di ar rhea due to vi ral patho gens
Ther apy of acute rotaviral in fec tions in chil dren 75 [Hilpert et al. 1987] Pro phy laxis for rotaviral in fec tions in hos pi ta lized chil dren 120 [Davidson et al. 1989] Ther apy of rotaviral in fec tions in in fants 75 [Mitra et al. 1995] Ther apy of rotaviral in fec tions in in fants 80 [Sarker et al. 1995] Ther apy of rotaviral in fec tions in in fants 135 [Ylitalo et al. 1998] 1.3. Di ar rhea due to protozoal patho gens Chronic cryptosporidiosis in AIDS patients 24 [Greenberg and Cello 1996] Cryptosporidiosis in HIV-in fected pa tients 37 (Subgroup) [Rump et al. 1992] Cryptosporidiosis in pa tients with AIDS 21 [Tzipori et al. 1987] Cryptosporidiosis in HIV-in fected pa tients 5 [Nord et al. 1990] Cryptosporidiosis in HIV-in fected pa tients 25 [Plettenberg et al. 1993] 
Neutralization of LPS (enterogenic translocation)
Stud ies in pa tients un der go ing ab dom i nal sur gery 40 [Bölke et al. 2002a] Stud ies in pa tients un der go ing car diac sur gery 60 [Bölke et al. 2002b] 3. Ther apy of GI-in fec tions with un known patho gens Dis tal co li tis 14 [Khan et al. 2002] Sjögren's syn drome 20 [Pedersen et al. 2002] Di ar rhea in AIDS pa tients 25 [Plettenberg et al. 1993] gens was lack ing and only about half of those with iden ti fi able etiologic patho gens caus ing di ar rhea re sponded to an ti bi ot ics. Ther apy of this dis ease us ing oral LC1 (10 g/day for 10 days) was in ves ti gated in a multicenter pi lot study in 37 im mu no de fi ciency pa tients with chronic di ar rhea. Of these pa tients, 29 were HIV + WR 4-6 (Wal ter Reed classification), 2 had com mon vari able im mu no de fi ciency (CVID), 1 had an im mu no de fi ciency of unknown eti ol ogy and 5 had graft ver sus host dis ease (GvHD) fol low ing allogeneic bone mar row trans plan ta tion. A good re sponse, in some cases with long-last ing nor mal iza tion of the di ar rhea was ob tained in 22 of the 33 treat ment pe ri ods and only 4 pa tients with AIDS were non-re spond ers. The mean daily stool fre quency de creased from 7.4 be fore treat ment with BCC to 2.2 at the end of the treat ment. A re cur rence of di ar rhea was observed in 12 pa tients dur ing the 4-week period post dose (41%) but 14 pa tients were free of di ar rhea for pe ri ods lon ger than 4 weeks (48%). In tes ti nal cryptosporidiosis dis appeared in 4 pa tients. The treat ment was also suc cess ful in 4 of the 5 patients with GvHD and no serious side effects were recorded in any of the patients [Rump et al. 1992] .
In a sub se quent pla cebo-con trolled Phase III clin i cal trial in 63 pa tients with HIVinfection, these find ings could not be confirmed. The in ves ti ga tors at trib uted this to the in tro duc tion of the HAART ther apy reg i men given to the pa tients dur ing the study since it was ob served that this ther apy caused marked changes in the spec trum of in tes ti nal pathogens (un pub lished re port, Biotest Pharma GmbH, Dreieich, Germany).
BCC in the treatment of hemorrhagic diarrhea in infants
In a Phase II pla cebo-con trolled, ran domized clin i cal study, 30 chil dren with acute hem or rhagic di ar rhea due to in fec tion with enterohemorrhagic E. coli (EHEC) were treated with LC1 [Huppertz et al. 1999] . During treat ment the me dian value for stool frequency de creased from three to one per day, whereas dur ing treat ment with pla cebo there was no change (p < 0.05). In the pa tients treated with BCC, the du ra tion re quired for a re duc tion in stool fre quency of at least 50% was shorter (p < 0.05).
Treat ment with BCC also in creased the ex cre tion of E. coli ex press ing intimin and EHEC-hemolysin al though the dif fer ences did not reach sta tis ti cal sig nif i cance. The results of this study with colostrum are clin ically im por tant since ther apy of EHEC diseases with an ti bi ot ics is con tro ver sial and an al ter na tive and safe ther apy other than BCC is not avail able. In deed, a num ber of an ti bi ot ics ac tu ally in crease the amount of Shiga toxin in vi tro [Kimmit et al. 2000 , Kohler et al. 2000 , Yoh et al. 1999 , Zhang et al. 2000 and Wong et al. [2000] showed in a pro spec tive clin i cal study that an ti bi otic ther apy in in fants with EHEC in fec tions in creases the risk of de velop ing a hemolytic uremic syn drome (HUS). Clin i cal stud ies car ried out later con firmed that an ti bi otic ther apy of EHEC in fec tions, in par tic u lar in those pa tients al ready de vel oping the syn drome, wors ened the course of disease and the fi nal out come [Bell et al. 1997 , Dundas et al. 2001 , Tap per et al. 1995 . The re sults of the study of Huppertz et al. [1999] are sup ported by the find ings of Lissner et al. [1996 Lissner et al. [ , 1998 where the serological anal y sis of LC1 re flect ing a block ade of Shiga toxin (STx) pro duc tion, points to the mode of action of BCC in the pro phy laxis of HUS.
Se vere di ar rhea and HUS in chil dren caused by EHEC have been re ported from coun tries through out the world and EHEC, like serotype O157, non-O157 are known to be im por tant caus ative agents of these diseases. EHEC can per sist in the gut of cat tle, goats, sheep, horses and geese. These do mestic an i mals con sti tute there fore di rect or in direct in fec tious routes af fect ing man, mainly in volv ing the in ges tion of con tam i nated food such as raw milk and raw milk prod ucts, uncooked meat, non-pas teur ized ap ple juice and may on naise. In fants liv ing in ru ral dis tricts are par tic u lar prone to in fec tions from these sources [Huppertz and Karch 1998 ].
EHEC are as so ci ated with nu mer ous vir ulence fac tors, the most im por tant of which are the Shiga tox ins, the Type III se cre tion sys tem and the re spec tive effector pro teins en coded by the lo cus of enterocyte ef face ment and plasmid-en coded pro teins such as EHEChemolysin, EspP and StcE (for re view see [Bielaszewska and Karch 2005 , Caprioli et al. 2005 , Karch 2001 , Nataro et al. 1998 , Orihuela et al. 2005 . In in fants with se vere hem or rhagic di ar rhea due EHEC in fec tions, the per cent age who de velop HUS is 5 -10% of all cases [Huppertz and Karch 1998 ].
The clin i cal and eco nomic im pact of these in fec tions and the need for hos pi tal ad mis sion to treat de hy dra tion and HUS is a grow ing bur den on the health ser vices [Tarr 1995] .
A com mon prob lem in car ry ing out clin ical tri als in pa tients with HUS is deal ing with ep i de mi o log i cal fac tors and their un pre dictabil ity and this prob lem arises be cause the res er voir for EHEC-type patho gens is dif ficult to iden tify [Huppertz et al. 1999] . The epi de mi ol ogy prob lems in Ger many in volv ing in fec tions with Shiga toxin-pro duc ing E. coli has been re viewed by Karch et al. [1997] and in a global context by Noris and Remuzzi [2005] .
The strict avoid ance of an ti bi ot ics in the ther apy of HUS has been ques tioned re cently but it is im por tant to note that the ther a peu tic ra tio nale for their use in HUS is based on only one meta-anal y sis of clin i cal stud ies, the proto cols of which dif fer mark edly in the qual ity stan dards ap plied [Phillips et al. 2005] . On the other hand, BCC prep a ra tions like LC1 and con se quently LC2N are ef fec tive in HUS both as treat ment and as pro phy lac tic agents es pe cially in children and are well tolerated.
Intra-enteral neutralization of lipopolysaccharides (endotoxins, LPS) with BCC in Gram-negative bacterial infections
The gut as an in ter face with the en vi ronment co mes into di rect con tact with both food stuffs and in fec tious or gan isms. In quanti ta tive terms it is the larg est or gan of the immune sys tem. The homeostatic mech a nisms in the gas tro in tes ti nal wall in volv ing per fusion with blood, lo cal de fense re ac tions (mucosa-as so ci ated lym phatic tis sues, MALT) and thus the in teg rity of the gut wall are essen tial for the in take of nu tri ents and pro tection against in vad ing patho gens and their toxins. The iso la tion of Gram-neg a tive bac te ria from the blood of pa tients with a sep sis syndrome or SIRS (sys temic in flam ma tory response syn drome) fre quently in di cates a source of in fec tion in the gas tro in tes ti nal or uri nary tract. Pre ven tion of the in va sion of patho gens us ing bac te ri cidal an ti bi ot ics is essen tial but can lead to the re lease of endo toxins CPS from the de cay ing patho gens followed by a mas sive sec ond ary re lease of cytokines such as interleukins and tu mor necro sis fac tor (TNF-a) from mononuclear cells with sub se quent tis sue dam age. It is known that the re lease of these fac tors in traumatic con di tions, e.g. fol low ing ma jor surgery, can cause mul ti ple or gan fail ure [Livingston and Deitch 1995] . The ex tent of the dam age to the GI-tract is de pend ent on the rate at which enterocytes are renewed and this depends critically on the rate of cell proliferation [Rittler et al. 2001] .
In ad di tion, any en dur ing def i cit of di etary pro tein sup ply causes a sup pres sion of cellmediated im mu nity whereas early enteral nutri tion of pa tients with intra abdomi nal injuries re duces the rate of com pli ca tions like sep sis and pneu mo nia [Hasenberg et al. 2007 , McClave et al. 1997 , Moore et al. 1986 ].
On the ba sis of the re sults ob tained in preclin i cal stud ies, two con trolled clin i cal tri als were car ried out with LC1 to ex am ine whether the com po nents in the prep a ra tion are able to bind LPS and in hibit invasory processes in the gas troin tes ti nal tract.
In the study of Bölke et al. [2002a] a to tal of 40 pa tients un der go ing sur gery of the gastro in tes ti nal tract were ran dom ized to re ceive ei ther LC1 (56 g daily for 3 days pre op er atively) or pla cebo and the course of the plasma endotoxin lev els and the endotoxin neu tra li za tion ca pac ity (ENC) were measured daily up to the 10th postop er a tive day. The re sults showed that the LPS-lev els in the LC1-group, ex pressed as AUC, were sig nif icantly lower than those in the con trol group (p < 0.05). The dif fer ence be tween the two groups was ap par ent on the day of the op er ation and the day af ter. The fall in endotoxin neu tral izing ca pac ity (ENC) was sig nif icantly lower in the pa tients treated with the BCC and the re turn to ini tial val ues was faster than in the con trol group (p < 0.006). In the sec ond study car ried out by these au thors, the ef fect of post op er a tive treat ment with BCC on in tes ti nal LPS translocation was ex am ined in a randomized, pla cebo-con trolled study in 60 pa tients un der go ing open-heart sur gery. The pa tients were treated perioperatively for 2 days with ei ther 42 g LC1 or pla cebo. The endotoxin con cen tra tion in the LC1-group was not sig nif i cantly lower and the dif fer ence in the ENC com pared to the con trol group did not reach sta tis ti cal sig nif i cance (p = 0.06). The dif fer ence in the con cen tra tion of interleukin-6 lev els was also non-sig nif i cant but the CRP-level was sig nif i cantly lower. The in ves ti ga tors rec om mend that fur ther stud ies should be car ried out using a higher preoperative dose of BCC and should be carried out in a larger number of patients [Bölke et al. 2002b] .
These two stud ies, per formed ac cord ing to GCP-guide lines in a to tal of 100 sur gi cal pa tients, show that LC1 pro duces a marked and in part sta tis ti cally sig nif i cant de crease, mea sured post op er a tively, in LPS in blood. This is fur ther ev i dence that one of the events ini ti at ing the sep sis syn drome fol low ing hypo volemic in sults in trau ma tized hypo tensive pa tients is the en try of bac te ria and lipo polysaccharides from the gut into the blood stream [Bahrami et al. 1998 , Claridge et al. 2000 , Pfeiffer et al.1996 .
Furthermore, anti-LPS ther apy with monoclonal antibodies in pa tients with hem or rhage and trauma re duces sep tic com pli ca tions [Demetriades et al. 1999] . It can be con cluded from these find ings, that if the GI-tract is a ma jor source of LPS, as the ev i dence suggests, then elim i na tion or re duc tion of intraluminal endotoxin, whilst main tain ing the mucosal bar rier func tion in in ten sive care patients, should pre vent or re duce the com pli cations of Gram-neg a tive sep sis and the de velop ment of mul ti ple or gan fail ure (MOV) [Fitzal et al. 2001] .
Of in ter est in this re gard is a pi lot study of Ulrich et al. [2001] in pa tients suf fer ing from ma jor burns where there is a high risk of Gram-neg a tive sep sis with le thal out come. These in ves ti ga tors de ter mined the LPS level in plasma be tween the sec ond and third day in such pa tients and ob served a marked in crease in the endotoxin con cen tra tion which reached a max i mum af ter 47 hours. Of the 7 pa tients ex am ined, 2 showed sharp in creases in plasma LPS and these 2 pa tients sub se quently developed sepsis and died.
As in the case of HUS pa tients, a fur ther ra tio nale for the ap pli ca tion of BCC in trauma pa tients is that the use of bac te ri cidal an ti bi otics can pro voke or re in force endotoxin emia [Holzheimer et al. 1996 , Seifert et al. 2002 .
LPS in mam mals can be ben e fi cial or detri men tal in a con cen tra tion-de pend ent manner and these ef fects in volve sen sor mol ecules such as the Toll-like re cep tors [Beutler and Rietschel 2003 ]. The mech a nisms by which BCCs neutralize LPS and pre vent their up take into the sys temic cir cu la tion is not well un der stood but lactoferrin, prob a bly the most im por tant in hib i tor in BCC of LPS, is able to bind the lipid A part of the LPS-mol ecule and this ap pears to act syn er gis ti cally with the anti-LPS-spe cific an ti bod ies in BCC in over-coming the ef fects of an in fec tion [Appelmelk et al. 1994 , Bellamy et al. 1992 , Fomsgaard 1990 .
BCC as an adjuvant in the therapy of patients with idiopathic pain syndrome
The stud ies car ried out with LC1 in these pa tients to date have been mainly ex plor atory and of ten sup ported by un pub lished ob ser vations re fer ring back to ear lier ob ser va tions with pa tients re ceiv ing immunotherapy. Mondorf and Duswald [1979] had treated 54 pa tients with her pes zoster and 18 pa tients with her pes sim plex with in tra ve nous immuno globulins class G (IVIG). Dur ing the in fusion the pa tients ex pe ri enced a re lax ation in skin ar eas with se vere le sions, and re ported a com plete re lief of their con com i tant neu ralgia. In a fur ther open de sign study car ried out later, in tra ve nous IgG (IVIG) was given to 6 pa tients re ceiv ing cytostatics to treat tu mors and who con com i tantly suf fered from extended her pes sim plex or zoster in fec tions with se vere at tacks of neu ral gia. All pa tients re ported im me di ate pain re lief dur ing or shortly after the infusion of IVIG (5 -10 g of IgG) [Mondorf et al. 1981] .
New in sights into the value of this approach have been ob tained from in ves ti gations at the Uni ver sity Hos pi tal, Wuerzburg, Ger many. The re search groups fo cussed on pa tients with in trac ta ble pain in whom pain re lief with es tab lished ther a peu tic reg i mens had failed [Goebel et al. 2002a] . In a pro spective multidose, open-la bel co hort study in 130 con sec u tive pa tients with chronic pain syndromes, in clud ing 48 cases with fibromyalgia and a to tal of 12 dif fer ent types of pain syn -drome, IVIG pro duced ap prox i mately 70% pain re lief in 20% of pa tients and in about half of the pa tients the level of pain re lief was above 25%. An in ter est ing find ing was that in pa tients re spond ing to IVIG treat ment, there was a re turn of al most in ces sant pain in a large pro por tion of those who had had an in fec tion, e.g. com mon cold or in flu enza a short time be fore or simultaneously. In other pa tients with chronic pain syn dromes, there were a higher pro por tion of pa tients with se rum an tibod ies against in tes ti nal patho gens when com pared to healthy con trols [Goebel et al. 2005] . These re sults prompted re search groups in the Uni ver si ties of Wuerzburg and Ox ford to look for suit able di ag nos tic pa rame ters in pa tients with de fined pain syndromes prior to their enrollment in further studies with IVIG [Goebel et al. 2003] .
In a clin i cal study in 40 pa tients with wide spread pain, 26 of whom had fibro myalgia, there was a lack of anti-in flam ma tory and an al ge sic Th2 cytokine ac tiv ity when com pared to age-and sex-matched con trols [Uçeyler et al. 2006] . In con trast to the con trol sub jects, pa tients had a sig nif i cantly lower rel a tive gene ex pres sion and lower se rum con cen tra tions of the Th2 cytokines, IL-10 and IL-4.
These re sults prompted the in ves ti ga tors to per form an un con trolled field trial at the Pain Center, Uni ver sity Hos pi tal, Wuerzburg, Ger many, in which BCC 20 g daily was admin is tered to ap prox i mately 1,000 pa tients with dif fer ent types of id io pathic syndromes. The aim of the in ves ti ga tion was to ex am ine the hy poth e sis that some pa tients had a postinfectious au to im mune dis ease re spon sive to treat ment with BCC. Sig nif i cant pain re lief oc curred in 30 -40% of pa tients de pend ing on the du ra tion and lo cal iza tion of the dis ease and there was a la tency of 4 -10 days af ter the treat ment be fore the full ef fect was de tect able [Sprotte, Uni ver sity Hos pi tal, Wuerzburg: un pub lished ob ser va tions]. Pa tients with idio pathic fa cial pain syn dromes, in clud ing trigeminus neu ral gia, glossopharyngeal neural gia, myo arthrop athy of the jaw and atyp i cal fa cial pain showed the high est re sponse rate and the short est la tency pe riod. Pa tients with chronic wide spread pain, in clud ing fibromyalgia with and with out ir ri ta ble bowel syndrome also showed a marked im prove ment in symp toms. It was con cluded that the pa tients in both groups had im pair ment in the mucosal bar rier func tion in the gas tro in tes ti nal tract and this find ing was sup ported by mea surements of the re sorp tion rates of var i ous sug ars [Goebel et al. 2002b ]. In the case of pa tients with fibromyalgia, 31 of 40 who were ex amined by this method and who had not been treated with IVIG or BCC pre vi ously re ported an ad verse re ac tion af ter the ap pli ca tion of the test sug ars. This di ag nos tic tool is there fore not suit able for rou tine clin i cal use.
Ac cord ing to the ex pe ri ence ob tained at the Wuerzburg Pain Cen ter, pa tients with chronic pain show ing a pos i tive re sponse to the treat ment with BCC, can also be suc cessfully treated with IVIG or SCIG and in many cases the re sults of these al ter na tive treatments are su pe rior to those us ing BCC. However, BCC has the ad van tage that pa tients respond ing can be treated in their homes (i.e. no infusion required).
Pa tients with chronic pain syn dromes given BCC, in con trast to those with out such symp toms, were of ten found to de velop a previ ously un re cog nized in tol er ance to the milk con stit u ents in BCC lim it ing their use in these pa tients. Re peated in take of BCC has also caused ex ac er ba tion of atopic der ma ti tis with skin le sions. Al though the tol er ance and reponse to BCC is gen er ally ex cel lent, in children with chronic pain, atopy (al ler gic bronchial asthma, rhi ni tis and atopic der ma ti tis) is not an in fre quent oc cur rence dur ing treatment with BCC [Sprotte, Uni ver sity Hospital, Wuerzburg: unpublished observations].
Mechanisms of action of BCC
Colostrum, as start ing ma te rial for BCC, in which the cel lu lar com po nents, most of the lipoproteins and some pro teins such as lactalbumin have been re moved, is a highly com plex mix ture of var i ous effector mol ecules [Kelly 2003 , van Hooijdonk et al. 2000 . This ex plains the wide range of pharmacodynamic ef fects de scribed in in vi tro sys tems, in an i mals and in clin i cal stud ies.
Synergisms of the colostral effector systems with the in nate defense of a host, especially of pa tients in fected with bac te rial patho gens, col o niz ing the gas tro in tes ti nal mu cosa ap pear to be suit able. For in stance, the ef fi cacy of antimicrobial pep tides as defen sins pro duced per ma nently by the cells in high con cen tra tions in the small in tes tine with a broad ac tiv ity range against Gram-nega tive and Gram-pos i tive bac te ria might rep resent ap pro pri ate can di dates in this re gard [Weh kamp et al. 2007 ].
Discussion including a comment on other possible applications of BCC
One of the pri mary tasks of the im mune sys tem in mam mals is the rec og ni tion of an tigens and their even tual forced elim i na tion. Bo vine colos trums and BCC made from it carry out this task and also other im por tant tasks such as the min i miz ing of in flam ma tory events which fol low ex po sure to an ti gens. The ru mi nant is unique in that there is a se lective pas sage of immunoglobulins class IgG into the mam mary gland prior to par tu ri tion so that the colos trums con tain large amounts of spe cific an ti bod ies. Gorman and Halliwell [1989] and Kelly [2003] , more re cently described in more quan ti ta tive terms the con stitu ents of the adap tive and the in nate im mune sys tem also pres ent in BCC acting together in a syn er gistic manner.
The ef fi cacy of BCC ther apy ap pears therefore to stem from those prop er ties of na tive colostrum which are im por tant for the health of newborn mam mals and these in clude the transfer in the humoral com po nents as so ci ated with in nate and ac quired ma ter nal im mu nity and the con com i tant pro vi sion of readily avail able nutri tional sub stances such as es sen tial amino acids.
The pharmacodynamic ef fects of BCC thus com ple ment or re place those of stan dard ther a pies, e.g. with an ti bi ot ics, an al ge sics and anti-in flam ma tory drugs.
One of the sites of ac tion of BCC is the mucosal sur face of the gas tro in tes ti nal tract and ac tive com po nents pre sum ably in ter act with the mu cosa-as so ci ated lym phatic tis sue (MALT). Al though the pro teins in BCC effec tor mol e cules, mainly IgG 1 , are readily degradable in the small in tes tine, more than 20% of IgG 1 reaches the ileocecal valve in an ac tive form [Roos et al. 1995] . As shown in Ta ble 1, the most clin i cal stud ies with BCC up to now have in volved the pro phy laxis or the early treat ment of in fec tious dis eases orig inat ing in the GI-tract. In the case of some syndromes due to bac te rial in fec tion, adjuvant treat ment us ing BCC in ad di tion to an an ti biotic is usu ally in di cated and suc cess ful.
Un like an ti bi ot ics, de vel op ment of drug re sis tance with BCC is not thought to be a prob lem with BCC and there is no ev i dence that the con stit u ents in duce en zymes involved in the me tab o lism of xenobiotics.
In pa tients with Gram-neg a tive sep sis the gut is usu ally the site for trans fer of LPS via lymphatics into the sys temic cir cu la tion. The mech a nisms in volved have been dis cussed in Part I and ev i dence has been pro vided for the intra-enteral neu tral iza tion of LPS by LC1 in patients.
The mech a nisms of ac tion of the ac tive com po nents in BCC is not known in de tail and the ear lier view that the g-glob u lins (mainly IgG 1 ) are the most im por tant ac tive prin ci ple must be in ter preted only as a working hy poth e sis. More re cent in ves ti ga tions, how ever, such as those of Bölke et al. [2002a] , have shown sta tis ti cally sig nif i cant de creases in LPS plasma lev els in pa tients un der go ing gas tro in tes ti nal sur gery af ter treat ment with LC1, and Seifert et al. [2002] us ing a rat model of Gram-neg a tive sep tic shock, found a syn ergy be tween anti-LPS specificities (IgG 1 ) and lactoferrin which is also pres ent in BCC and this phe nom e non ap pears to have its clin i cal coun terpart.
The LPS-re lease phe nom e non, trig gered on the other hand by bac te ri cidal an ti bi ot ics, has been con firmed in clin i cal stud ies by several groups [Dofferhoff et al. 1991 , Prins et al. 1995 . Cer tain types of b-lactam an ti bi ot ics seem to re lease more LPS than oth ers and this prop erty is strongly cor re lated with penicillin-binding pro tein-3 [Jack son and Knopp 1992] .
These find ings are rel e vant since there is much ev i dence to show that the gut is a lo cus minoris resistentiae for in fec tions and a res ervoir for nox ious sub stances like LPS and Shiga-like tox ins when the gut wall is damaged, e.g. dur ing hypoperfusion states or during malnutrition.
A re cently pub lished re view, how ever, casts doubt on the role of LPS as a ma jor ini tia tor of sep tic pro cesses when the treat ment of pa tients with anti TNF-a and anti-LPS in terven tions fail [Riedemann et al. 2003 ]. The neu tral iza tion in situ of LPS, a ma jor toxin from Gram-neg a tive bac te ria, by BCC is attrib ut able to antitoxic effector mol e cules like lactoferrin and spe cific IgG an ti bod ies. The com bi na tion of these phar ma co log i cal ef fects ac counts for the ef fi cacy of BCC in the preven tion of Gram-neg a tive sep tic shock in patients. A pro found re view ar ti cle deal ing with the pathophysiological role of CPS in clin i cal med i cine was pub lished by Al ex ander and Rietschel [2001] .
Com par i son of data on pa tients with sepsis of non-en teric or i gin with those hav ing enterosepsis may not be very in for ma tive since the site of in fec tion and stage of the disease have a marked in flu ence on the course of the dis ease and the ef fects of ther apy. En teric sep sis com prises about 20% of all cases of sep sis [Mar tin 1991] . Ev i dence from ex per imen tal [Fitzal et al. 2001] and clin i cal stud ies [Demetriades et al. 1999] point to the gas troin tes ti nal en try of bac te ria and pres ence of LPS fol low ing trauma and hem or rhage with hypoperfusion of the gut wall as the ini ti at ing events in sep sis. Break down in the in teg rity of the gut bar rier would ag gra vate or gan injury in dis tal re gions of the body be cause of me di a tors, in par tic u lar those car ried in the mesenteric lymph [Magnotti et al. 1998 ]. On the other hand, the sys temic ad min is tra tion of anti-endotoxin agents neu tral izes the plasma endotoxin and can pro tect the vi tal or gans against the in ju ri ous ef fects of these substances [Bahrami et al. 1997 , Bahrami and Schlag 1995 , Bauer and Welch 1996 , Demetriades et al. 1999 , Yao et al. 1995 .
Sep sis is one of the most fre quent causes of death af ter a ma jor burn in jury and is usually at trib ut able to an in fec tion in volv ing Gram-neg a tive or gan isms and the re lease of LPS [Ulrich et al. 2001] . When more than 40% of to tal body sur face is af fected, endotoxin plasma lev els reach a max i mum be tween the third and the fourth day [Ulrich et al. 2001 , Winchurch et al. 1987 , Yao et al. 1995 . The au thors de scribe this as a con sequence of in creased colonization of the gut mu cosa by Gram-neg a tive or gan isms and con com i tant influx of LPS from burnt tissue.
Nev er the less, LPS mol e cules resorbed con tin u ally from mucosal sur faces such as the GI-tract with a sur face area of 300 m 2 have a phys i o log i cal func tion within a lim ited range of con cen tra tions within the mam ma lian defence networks.
Endotoxin is one of the most po tent immunostimulants, which via the ac ti va tion of Toll-like (TLRs) re cep tors acts as a per manent de fense sys tem against var i ous pathogens. An in fected host, on the other hand, would over re act in the pres ence of large quan ti ties of LPS, in par tic u lar with a mas sive lib er a tion of TNF-a and other in flam ma tory cytokines [Beutler and Rietschel 2003] .
Ir re spec tive of the patho log i cal background, it is al ways cor rect in the case of sep sis treat ment, along with fo lic acid ap pli ca tion and an ti bi otic ther apy, to in hibit endo toxins and the ef fects of these.
In a clin i cal trial in chil dren with se vere hem or rhagic di ar rhea due to in fec tion with enterohemorrhagic E. coli (EHEC), LC1 was able to elim i nate these or gan isms and re duce the dan ger of de vel op ing a hemolytic uremic syn drome (HUS), a dis ease which in in fants is of ten fa tal or can cause se vere damage [Huppertz et al. 1996] . This re sult pro vides ev i dence that the an ti body specificities of the g-glob u lins pres ent in BCC are con sis tent with their abil ity to elim i nate in the hu man GI-tract Esch e richia coli-expressing Shiga tox ins 1 and 2, intimin and EHEC-hemolysin [Lissner et al. 1996] . Be cause of the risks of an ti bi otic treat ment in pe di at ric pa tients and its ineffectivity in pre vent ing HUS, treat ment with polyvalent BCC is the ap par ent firstchoice ther apy in pa tients with EHEC.
Safety aspects regarding the use of BCC in man
A risk anal y sis of the cases treated longterm with a polyvalent BCC pri mar ily must in volve the tech ni cal cri te ria of the pro duction pro cess, the re sults of pharmaco dynamic in ves ti ga tions and the clin i cal stud ies and case re ports, ex am ples of which are de scribed in this review. i) The raw ma te rial e.g. for LC2N orig i nates from an i mal herds kept un der strict vet er inary-con trolled con di tions. It is ob tained from New Zea land colostrum and thus from colos trums orig i nat ing from a country cer ti fied as BSE-free. ii) The pro duc tion of LC1 is car ried out accord ing to GMP. Ho mo ge ne ity of pro duction lots is at tained by us ing a colostrum pool from sev eral hun dred colostrum col -lec tions and strict com pli ance with the stan dards of pro duc tion (GMP). Since Lactobin N (LCZN) is a com plex mix ture of pro teins, this mea sure avoids the gen era tion of new al ler genic de ter mi nants in the pro duc tion pro cess. In this re gard, par tic u larly infants are at risk of de vel oping cow's milk al lergy af ter the ces sa tion of breast-feed ing when their in tes ti nal immune sys tem be comes ex posed to these pro teins in other food stuffs [Heyman 1999 ]. iii) There is no ad di tion of for eign ma te ri als dur ing the pro duc tion pro cess of LC2N and LC1. iv) An i mal tests on LC1 have shown no ev idence of tox ic ity (fin ger print anal y sis and mi cro bi o log i cal test pro ce dures based upon the IgG 1 -con cen tra tion have demon strated bioequivalence be tween LC1 and LC2N). v) No ad verse re ac tions were re ported with LC1 in the three Phase 1 clin i cal tri als in healthy sub jects. In the clin i cal tri als in pa tients, Lactobin pro duced no se vere adverse re ac tions with the ex cep tion of patients with a pro longed his tory of chronic pain. Re sorp tion tests with var i ous sug ars have shown that pa tients with chronic pain are able to ab sorb macromolecules from the gut [Goebel et al. 2002b] . The risk of sen si ti za tion re ac tions against non-degraded pro teins means that BCC might there fore be con tra in di cated in patients with ce liac dis ease and chronic enter i tis such as Crohn's disease. vi) Lac tose in tol er ance: ab sorp tion of lac tose re quires lactase ac tiv ity in the brush border of the sen si tiz ing small in tes tine. Lactose in tol er ance can oc cur in in fants and young chil dren with acute diarrheal disease but the clin i cal sig nif i cance of this is lim ited ex cept in more se verely af fected chil dren. Symp toms of lac tose in tol erance are rel a tively com mon in older children and ad o les cents but signs of intes ti nal in jury re sult ing from it are uncom mon. Lac tose in tol er ance dif fers from milk pro tein sen si tiv ity since a sen si tiv ity to milk pro teins in volves the im mune system and can cause le sions of the in tes ti nal mu cosa. Dur ing the first 3 months of life, 2 -5% of in fants ex hibit symp toms of cow's milk pro tein intol er ance which gener ally re solves it self be fore reach ing the age of 1 year (for re view see Hagemann [1999] ).
Sec ond ary lactase de fi ciency can oc cur later in life the eti ol ogy of which most of ten lies in an in fec tion, e.g. due to rota virus. Symp toms can also arise in ce liac dis ease, Crohn's dis ease and im mune-re lated dis eases [Heyman 2006] or enteropathies as can oc cur in pa tients with chronic pain syn dromes. The pro por tion of pa tients at the Wuerzburg Pain Cen ter pre sent ing with symp toms of in tol erance to in gested lac tose is ap prox i mately 10%. The lac tose in BCC, like that in LC prep a ra tions, causes a re in force ment of pain sen sa tions in ad di tion to caus ing typ i cal gastro in tes ti nal dis or ders [Sprotte, unpub lished ob ser va tions].
Potential clinical indications for BCC
Some po ten tial in di ca tions for the clin i cal ap pli ca tion of BCC have been men tioned above. The mul ti ple effector mech a nisms con tained in BCC can in hibit or de stroy human patho gens and can neu tral ize vir u lence fac tors and lib er ated tox ins. They are also involved in antiphlogistic ef fects. The ques tion arises, whether other pa tient pop u la tions in ICU such as trans plant re cip i ents might also ben e fit from sup ple men tary treat ment with BCC. The se lec tive de con tam i na tion of the gut in pa tients af ter mul ti ple trauma, se vere sur gi cal stress and in tense immunosup pression ther apy with an ti bi ot ics has been the subject of con tro ver sial dis cus sion since its in troduc tion in 1984 [Stoutenbeck et al. 1984] . In spite of a re duc tion in mor tal ity rates in clin ical stud ies in ICU pa tients re ceiv ing com bina tions of non-ab sorbed antimicrobial and top i cal oropharyngeal an ti bi ot ics, con cern ex ists re gard ing the de vel op ment of bac te rial re sis tance [de Jonge et. al. 2003 , Vin cent 2003 . Im ple ment ing the ad di tional treat ment with BCC into the cur rent scheme of se lec tive gut de con tam i na tion could rep re sent an improve ment but ev i dence in the form of data from ap pro pri ate clin i cal stud ies is needed. The ra tio nale be hind such ther apy in ICU patients could be the erad i ca tion of aerobic, potential ly pathogenic microorganisms from the stom ach and gut and the preservation of useful indigenous anaerobic flora.
In the same con text Bölke et al. [2002a] for ex am ple, ad vo cate the perioperative treatment with BCC as a prom is ing new strat egy for pa tients un der go ing liver trans plan ta tion, thereby pro tect ing the trans planted or gan for in stance against a mas sive CPS translocation from the gut.
The in hi bi tion of enteral LPS-trans fer might also be ben e fi cial in pa tients with ma lig nant tu mors since such pa tients may be come anorexic due to in creased ac tiv i ties of TNF-a in duced by LPS. In creased TNF-a ac tiv i ties in tu mor pa tients and the ef fects of this might have been at trib uted to in duc tion of CD14 on monocytes in blood and within the tu mor.
It can be spec u lated that re duc tion in the in tes ti nal LPS-in flux would de crease TNF-a ac ti va tion and pre vent an orexia in tu mor patients. In sup port of this view is the ob ser vation that in pa tients with pan cre atic can cer the ex pres sion of CD14 in both Kupffer cells and blood monocytes is in creased. This change would ren der them more sen si tive to bac te rial LPS and in crease the like li hood of a proinflammatory re sponse with the con se quent development of cachexia. Bitzan et al. [1998] ob tained ev i dence that the col o ni za tion of gas tric ep i the lial cells by Helicobacter pylori can be blocked by polyvalent BCC such as LC1 and that this might be use ful as an adjuvant in treat ing gastroduodenal dis ease in clud ing gas tric malig nan cies when this or gan ism is pres ent. The causal re la tion ship be tween the oc cur rence of H. pylori and a va ri ety of gas tric dis eases has been re ported in de tail in a more re cent review by Brenner and Rothenbacher [2005] .
In a clin i cal study car ried out in 24 in fants with H. pylori in fec tions, pu ri fied colostrum from cows vac ci nated with the or gan ism, how ever, failed to cure the in fants of the disease [Casswall et al. 1998 ].
A fur ther pos si ble in di ca tion for the use of BCC is the treat ment of in ju ries to the small in tes tine caused by nonsteroidal anti-in flamma tory drugs (NSAID). The ra tio nale for clin i cal in ves ti ga tions on this topic stems from an i mal ex per i ments with BCC in rats was de scribed in Part I of this review.
In two well-con trolled clin i cal stud ies, Playford et al. [2001] used a non-in va sive marker to de ter mine the pres ence of gastrointestinal in jury and in creased gut permeability and to ex am ine the ef fect of BCC (Vi a ble Bioproducts, Turku, Fin land) in patients tak ing NSAIDs. In one of these stud ies, a ran dom ized cross over trial in healthy male sub jects, changes in gut per me abil ity, expressed as lactulose/rhamnose re sorp tion ratios, were com pared be fore and af ter a 5-day treat ment with 50 mg indomethacin given orally 3 times daily whilst ad min is ter ing 125 ml colostrum or whey pro teins (con trol) 3 times daily. The find ings showed that indomethacin caused a 3-fold in crease in gut per me abil ity in the con trol arm but no sig nif icant in crease dur ing the coadministration of colostrum.
In the sec ond study on the ef fect of colostral and con trol so lu tions (125 ml, for 7 days) on gut per me abil ity in pa tients (n = 15) on long-term NSAID ther apy, the ini tial perme abil ity ra tios were low and not in flu enced by coad min is tra tion of the test compounds. Fur ther stud ies are there fore needed to con firm that bo vine colostrum prep a ra tions pre vent NSAID-in duced gas tro in tes ti nal dam age.
Cesarone et al. [2007] re ported a clin i cal study in 144 sub jects with ages in the range of 30 -80 years, com pared the ef fi cacy of oral colostrum (900 mg/day for 2 months; Concon, Guna, Srl., Milano, It aly) with vacci na tion against in flu enza. The study pop u lation was di vided into three groups: sub jects re ceiv ing BCC who had been pre vi ously vacci nated against in flu enza vi rus, sub jects without pre vi ous vac ci na tion who also re ceived BCC and Group 3 con tain ing sub jects who re ceived no pro phy lac tic treat ment. The results showed that the av er age num ber of fluepisodes in sub jects treated with colostrum was significantly lower than in sub jects not receiv ing colostrum. The num ber of days with flu was 3 times higher in the non-colostrumtreated sub jects. The in ci dence of events asso ci ated with flu was higher in the vac ci nated than in the colostrum-treated in di vid u als (p < 0.05). Pre lim i nary data in healthy vol un teers im mu nized with at ten u ated Sal mo nella typhi oral vac cine and who con com i tantly consumed liq uid pre packed bo vine colostrum tended to have greater in creases in spe cific IgA (ELISPOT as say and flow cytometry in vi tro) in com par i son to vol un teers not treated with colostrum [He et al. 2001] . The in crease in spe cific sIgA is re garded by the au thors as the key mechanismof flu-pre ven tion by BCC.
Safety and efficacy of BCC administration to humans -conclusions
In con clu sion, the re sults of Phase I studies in hu man vol un teers and Phase II/III studies in pa tients have dem on strated that the pharmacodynamic ef fects of BCC ob served in preclin i cal ex per i ments have their ther apeu tic coun ter part in a num ber of clin i cally im por tant dis eases al though there is a need for con fir ma tory in ves ti ga tions in most ar eas. On the other hand, the im pli ca tions of the con sid er able vol ume of case study data, e.g. those held at the data bank of the Pain Clinic in Wuerzburg, should not be un der es ti mated. The re sults of the stud ies are con sis tent with the view that BCC ther apy is a "sup port ive" ther apy, i.e. the pharmacodynamic mech anisms evolve from the multifold ac tive compo nents pres ent and that these mod u late the body defense pro cesses (Fig ure 1 gives an out line of the present medical experience to treat patients with BCC).
The safety of BCC has been well-es tablished in the clin i cal stud ies with LC1 and up to now no ma jor or unpredictable risks have been re ported. In tol er ance to lac tose, a compo nent in BCC prep a ra tions, and milk proteins can oc cur but such re ac tions can gen erally be an tic i pated from the di etary habits of the patient.
Since it is clear that BCC prep a ra tions are safe and ef fec tive in a broad range of in di cations, this unique form of peroral pas sive immu ni za tion de serves attention.
